Ozempic (semaglutide) lowers blood sugar in type 2 diabetes through several overlapping mechanisms: it triggers insulin release when glucose is high, slows digestion so sugar enters your bloodstream more gradually, and reduces appetite. Across major clinical trials, it lowered A1C by 0.6 to 1.6 percentage points compared to placebo or other treatments. Here’s how each of those mechanisms works in your body and what the drug actually does beyond blood sugar control.
How It Triggers Insulin at the Right Time
Ozempic mimics a natural gut hormone called GLP-1 that your body releases after eating. GLP-1 tells your pancreas to produce more insulin, but only when blood sugar is elevated. This “glucose-dependent” action is important because it means the drug carries a lower risk of causing dangerously low blood sugar compared to older diabetes medications like sulfonylureas, which push insulin out regardless of what your glucose is doing.
At the same time, Ozempic suppresses glucagon, a hormone that signals your liver to release stored sugar. In type 2 diabetes, glucagon levels are often inappropriately high, flooding the bloodstream with glucose you don’t need. By dialing glucagon down during and after meals, Ozempic helps keep that extra sugar from entering circulation in the first place.
Slowing Digestion to Flatten Blood Sugar Spikes
One of the most powerful things Ozempic does has nothing to do with insulin. It slows the rate at which food leaves your stomach, a process called gastric emptying. When food moves into your small intestine more gradually, glucose trickles into your bloodstream instead of flooding it all at once. Gastric emptying speed accounts for roughly a third of the initial blood sugar spike you see in the first 15 to 30 minutes after eating. In research on GLP-1 given intravenously, this slowing effect was so dominant that it actually outweighed the drug’s insulin-boosting effects, meaning the slower digestion alone was enough to blunt post-meal glucose surges.
The drug achieves this by relaxing the upper portion of the stomach, reducing contractions in the lower stomach, and tightening the valve between the stomach and small intestine. The practical result: food sits in your stomach longer, you feel full sooner, and your post-meal blood sugar readings look significantly flatter.
Weight Loss and Why It Matters for Diabetes
Ozempic produces meaningful weight loss, which itself improves insulin sensitivity and blood sugar control. In clinical trials of people with type 2 diabetes and overweight or obesity, patients on the standard 2 mg dose lost roughly 7 to 8% of their body weight, compared to about 2% on placebo. Higher experimental doses pushed that to nearly 11% in trial settings.
This weight loss comes partly from the slower gastric emptying (you feel full longer) and partly from effects on appetite-regulating areas of the brain. Reduced appetite was reported in about 5% of semaglutide users in clinical studies. For someone with type 2 diabetes, losing even 5 to 10% of body weight can substantially improve how well the body responds to its own insulin, creating a positive feedback loop where the medication works better over time as weight drops.
What the Dosing Schedule Looks Like
Ozempic is a once-weekly injection, and the dose ramps up gradually to minimize side effects. You start at 0.25 mg weekly for the first four weeks. This starting dose isn’t meant to control blood sugar; it’s purely to let your body adjust. After those four weeks, the dose increases to 0.5 mg, which is the first true maintenance dose.
From there, your doctor may increase to 1 mg and eventually to a maximum of 2 mg weekly, with at least four weeks between each step up. The right maintenance dose depends on how your blood sugar responds and how well you tolerate the medication. For people with chronic kidney disease, the recommended maintenance dose is 1 mg once weekly.
Common Side Effects
Digestive symptoms are the most frequent issue, and they’re a direct consequence of the drug slowing your gut. In a large meta-analysis of GLP-1 receptor agonist trials, semaglutide caused nausea in about 21.5% of users, diarrhea in roughly 10.6%, vomiting in 9%, constipation in 8%, and indigestion in 8%. Decreased appetite occurred in about 5% of users.
These symptoms tend to be worst during dose increases and improve over the following weeks as your body adjusts. The gradual titration schedule exists specifically to soften this transition. Most people find that nausea fades considerably by the time they’ve been on a stable dose for a few weeks, though some experience it intermittently throughout treatment.
Heart and Kidney Protection
Ozempic does more than manage blood sugar. In cardiovascular outcome trials, semaglutide reduced major cardiovascular events (a composite of heart attack, stroke, and cardiovascular death) by 21%, with a hazard ratio of 0.79 compared to placebo. For a population with type 2 diabetes, which carries roughly double the cardiovascular risk of the general population, this is a significant benefit that goes well beyond glucose numbers on a lab report.
The kidney data is equally striking. The FLOW trial, which enrolled over 3,500 people with type 2 diabetes and significant kidney disease, was stopped early because semaglutide showed a 24% reduction in a composite outcome of kidney function decline, kidney failure, and death from kidney or cardiovascular causes. It also slowed the annual loss of kidney filtration rate by about 1.16 mL/min per year. To put that in perspective, people with diabetic kidney disease can lose 3 to 5 mL/min annually, so preserving over a full unit each year is clinically meaningful over a decade.
Where Ozempic Fits in Treatment Guidelines
The American Diabetes Association’s 2025 guidelines position GLP-1 receptor agonists like Ozempic as a preferred therapy in several specific situations. For people with type 2 diabetes who also have cardiovascular disease or high cardiovascular risk, guidelines recommend a GLP-1 agonist regardless of current A1C level. The same applies for people with chronic kidney disease, where semaglutide is recommended both for blood sugar management and to slow kidney decline.
For people with type 2 diabetes who don’t have these additional risk factors, metformin remains the most common starting medication. But the guidelines now also state that when insulin would otherwise be the next step, a GLP-1 agonist is preferred over insulin in people without evidence of insulin deficiency, because it offers comparable or better blood sugar control with lower risk of low blood sugar episodes and weight gain. If insulin is already being used, adding a GLP-1 agonist is recommended for improved glucose control, weight benefits, and fewer hypoglycemic episodes.
Who Should Not Take Ozempic
Ozempic carries an FDA black box warning, the most serious type of drug warning, related to thyroid tumors. In animal studies, drugs in this class caused thyroid tumors, including a rare type called medullary thyroid carcinoma. Anyone with a personal or family history of medullary thyroid cancer, or a genetic condition called multiple endocrine neoplasia syndrome type 2 (MEN2), should not use semaglutide. While the relevance to humans isn’t fully established, the risk was serious enough for the FDA to make it a hard contraindication rather than a caution.
People with a history of pancreatitis should discuss the risks carefully with their doctor, as GLP-1 agonists have been associated with pancreatic inflammation in some cases. The drug is also not appropriate for type 1 diabetes or for treating diabetic ketoacidosis.